Navigation Links
Drug-based on MGH discovery may significantly improve treatment of dangerous blood disorder
Date:1/31/2008

Two clinical trials of the novel drug romiplostim (Nplate) show that it significantly improved platelet levels in patients with chronic immune thrombocytopenic purpura (ITP), a hematologic disorder that can cause uncontrolled bleeding. An international research team reports Phase 3 trial results for the drug, which duplicates the action of a natural hormone discovered by a Massachusetts General Hospital (MGH) investigator, in the February 2 issue of The Lancet.

Many ITP patients have had to choose between no therapy or a treatment with limited efficacy and potentially serious side effects, says David Kuter, MD, DrPhil, director of Clinical Hematology at MGH and lead author of the Lancet study. The low toxicity and high response to this drug may convert a potentially life-threatening condition to one that can be easily managed with a weekly injection.

ITP is a chronic disorder in which the immune system destroys platelets, blood cells that help prevent bleeding. While some ITP patients experience only increased bruising, others may have serious bleeding and occasionally dangerous hemorrhage. Recent investigations suggest that, in addition to the destruction of existing platelets, ITP also may be due to reduced platelet production. Currently available treatments for ITP including steroid drugs, which have significant side effects, and removal of the spleen (splenectomy) are designed to reduce platelet destruction and may be ineffective in many patients.

Thrombopoietin is the natural regulator of platelet production. Kuter was one of the original discoverers of the hormone in 1994 and has been active in developing thrombopoietic drugs ever since. Romiplostim is a unique peptibody a peptide antibody that stimulates platelet production by mimicking the action of thrombopoietin. Earlier Phase 1 and 2 trials have shown that romiplostim increases platelet production in healthy volunteers and in short-term treatment of ITP patients.

The double-blinded Phase 3 trials were conducted at 35 sites in the U.S. and Europe. One trial enrolled 63 splenectomized patients, the other included 62 patients who retained their spleens. Both groups were randomly assigned to receive either romiplostim or a placebo in weekly injections during the 24-week study period. Participants platelet levels were monitored during the trial, and dosage was adjusted to achieve a target platelet count of 50,000/ml.

Among the 42 splenectomized patients who received romiplostim, nearly 80 percent reached the target platelet count during at least four weeks of the study, and 38 percent achieved a durable response, maintaining a target platelet count during at least six of the last eight weeks of the study. In the non-splenectomized patients, 88 percent had at least four target platelet count measurements, with 61 percent achieving a durable response.

More than half the patients receiving romiplostim were able to discontinue all other ITP medications they were taking, and 35 percent reduced other therapies. While over half the participants in the placebo groups of both studies needed rescue medications to treat or prevent bleeding episodes, significantly fewer of those receiving the active medication needed such treatment.

Were seeing dramatic results for this totally new approach to treating people with ITP, Kuter says. Ive been working on the development of thrombopoietin since 1983, and its very gratifying to participate in its discovery, purification, drug development and now the studies showing its clinical effectiveness. He adds that his MGH team and other researchers are conducting other romiplostim trials and will continue to investigate the drugs usefulness for treating ITP and other conditions of reduced platelet production, such as those caused by cancer or cancer treatment.


'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Dannemiller Memorial Education Foundation and GR MedEd, Inc. Announce Oncology Summit: From Discovery to Delivery
2. A New Series Is Born on Discovery Health
3. ITRAC on track and bridging gap between academic research and applied discovery
4. Discovery opens door to personalized asthma therapy
5. Linguamatics and 81qd Sign Multi-Year Collaboration in Knowledge Discovery for Product Life Cycle Management
6. Fight against hay fever and other allergies helped by new immune system discovery
7. Discovery Healths Fifth Annual National Body Challenge Takes a Stand Against Obesity by Offering the Keys to Adopting a Healthy, Active Lifestyle
8. Overweight Twins Battle the Bulge and Gain A New Lease on Life in National Body Challenge: Twins Edition on Discovery Health
9. Kaiser Permanente and Discovery Health Team Up to Fight Childhood Obesity Epidemic
10. Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award
11. OHSU Cancer Institute research discovery opens new window to understanding chronic myeloid leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from biotech, pharmaceutical, ... and 31st at The Four Seasons Hotel Boston. , The Boston CEO ... offering exclusive access to key decision makers who influence deal making and investment. ...
(Date:5/26/2017)... ... May 26, 2017 , ... Somnoware, ... NOX-T3 portable sleep monitor with its Somnoware Sleep Device Interface (SDI). Somnoware SDI ... diagnostic device operations. With this platform, initializing devices and importing studies are just ...
(Date:5/26/2017)... ... May 26, 2017 , ... via seating ... mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper Mesh ... to partner with Cupron® to provide customers with a game changing chair that ...
(Date:5/26/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... being discussed by President Donald Trump and the rest of the world. Donald Trump ... peace talks in the continuous battle between Israel and Palestine. The world’s eyes are ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral ... new, informational blog post on insurance options. If a Bay Area patient has to ... save time and money. Visiting an in-network provider for a second opinion can ensure ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)... -- Two Bayer U.S. Pharmaceutical leaders received top awards from ... th Woman of the Year event ... mission of furthering the advancement and impact of women ... Powell-Steffen , senior director of brand activation and inside ... Howe , a regional business manager for New England ...
(Date:5/11/2017)... 2017  Thornhill Research Inc. ( Toronto, ... $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by the ... Corporation (CCC) ( Ottawa, Ontario, Canada ... general anesthesia to patients requiring emergency medical procedures ... Marine Corps have been a longtime partner with ...
(Date:5/10/2017)... Md. , May 10, 2017 CSSi, ... solutions for the clinical research industry, is proud to ... www.CSSiEnroll.com . The new website features both enriched content ... user experience and enhances the company,s already well-established position ... industry. "After many months of hard ...
Breaking Medicine Technology: